Urogen Pharma (URGN) Institutional Ownership

91.29% of Urogen Pharma's stock is owned by institutional investors. Learn more on URGN's institutional investor holdings.

Of the 136 institutional investors that purchased Urogen Pharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Paradigm Biocapital Advisors LP ($4.47M), Toronto Dominion Bank ($3.50M), RA Capital Management L.P. ($3.21M), BlackRock Inc. ($3.20M), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC ($3.04M), Jefferies Financial Group Inc. ($2.20M), and Soleus Capital Management L.P. ($2.19M).

Institutional investors have bought a total of 20,564,788 shares in the last 24 months. This purchase volume represents approximately $545.31M in transactions.

Of the 42 institutional investors that sold Urogen Pharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Millennium Management LLC ($894.79K), Healthcare of Ontario Pension Plan Trust Fund ($738.03K), Tang Capital Management LLC ($650K), JPMorgan Chase & Co. ($388.27K), Voloridge Investment Management LLC ($251.99K), Nuveen LLC ($204.93K), and Bank of America Corp DE ($158.51K).

Institutional investors have sold a total of 4,320,168 shares in the last 24 months. This volume of shares sold represents approximately $95.83M in transactions.